Previous 10 | Next 10 |
Expectations can be irrational and still have power – that’s about the only reason I can see for why Neurocrine ( NBIX ) shares were as weak as they were coming out of the company’s JPMorgan Healthcare Conference presentation. Investors went into this conference with inf...
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with this Read more ...
Xenon ’ s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for Milestone Payments Based on the Advancement of Partnered Programs Experienced Biotech Executive, Dr. C...
On a preliminary basis , Neurocrine Biosciences (NASDAQ: NBIX ) expects Ingrezza (valbenazine) sales in Q4 and 2019 to be ~$238M (+83%) and ~$753M (+84%), respectively. More news on: Neurocrine Biosciences, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
SAN DIEGO , Jan. 12, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today provided an update on its business performance, including preliminary net product sales results for 2019, and key commercial and clinical development milestones for 2020. Kevin Gorman , Chief...
SAN DIEGO and ALLSCHWIL, Switzerland , Jan. 10, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Idorsia Ltd. (SIX: IDIA) announced an amendment to the agreement that was originally signed in 2019 granting Neurocrine Biosciences an option to license ACT-709478, a pot...
After shares lost ground following a clinical trial failure in Tourette syndrome in December 2018, Neurocrine Biosciences (NASDAQ: NBIX) bounced back in 2019 with an eye-popping 50.5% return, according to S&P Global Market Intelligence. The biotech 's market-beating performance was...
This list is a snapshot of the best healthcare stocks for an entire decade, from 2010 to 2020. As such, some magnificent stocks are excluded, simply because of the measurement period. For instance, Axsome Therapeutics had an amazing 3,578% return in 2019. And yet Axsome's fantastic 2019 r...
GW Pharmaceuticals (NASDAQ: GWPH) paved the way for modulating the cannabinoid pathway and turning that field of science into valuable prescription therapeutics. Over the past five years, GW transitioned from a promising idea to a commercial reality with two approved drugs in the U.S. and Eu...
SAN DIEGO , Jan. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 38 th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. Pacific Time ( 2:30 p.m. Eastern Time ) on Monday, Jan. 13, 2020 , in San Francisco . Kevin Gorman , Chief Execu...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...